KETOROLACO TROMETAMOL ACCORD 30 MG/ML SOLUCION INYECTABLE EFG Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ketorolaco trometamol accord 30 mg/ml solucion inyectable efg

accord healthcare s.l.u. - ketorolaco trometamol - soluciÓn inyectable - 30 mg inyectable 1 ml - ketorolaco trometamol 30 mg - ketorolaco

KETOROLACO TROMETAMOL NORMON 30 mg/ml SOLUCION INYECTABLE EFG Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ketorolaco trometamol normon 30 mg/ml solucion inyectable efg

laboratorios normon s.a. - ketorolaco trometamol - soluciÓn inyectable - 30 mg - ketorolaco trometamol 30 mg - ketorolaco

KETOROLACO TROMETAMOL QUALIGEN 30 MG/ML SOLUCION INYECTABLE EFG Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ketorolaco trometamol qualigen 30 mg/ml solucion inyectable efg

neuraxpharm spain s.l. - ketorolaco trometamol - soluciÓn inyectable - 30 mg - ketorolaco trometamol 30 mg - ketorolaco

Ketorolac Kabi New Zealand - engelsk - Medsafe (Medicines Safety Authority)

ketorolac kabi

fresenius kabi new zealand limited - ketorolac trometamol 30 mg/ml - solution for injection - 30 mg/ml - active: ketorolac trometamol 30 mg/ml excipient: ethanol hydrochloric acid sodium chloride sodium hydroxide water for injection - ketorolac kabi is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral* formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (conversion from intramuscular to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. * ketorolac oral formulation is available from other brands. ketorolac is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of ketorolac in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC TROMETAMOL ROMPHARM 30 mg/ml Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ketorolac trometamol rompharm 30 mg/ml

rompharm company s.r.l. - romania - ketorolacum tromethamin - sol. inj. - 30mg/ml - antiinflamatoare si antireumatice nesteroidiene derivati ai acidului acetic si substante inrudite

KETOROLACO KABI 30 MG/ML SOLUCION INYECTABLE EFG Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ketorolaco kabi 30 mg/ml solucion inyectable efg

fresenius kabi espaÑa, s.a.u. - ketorolaco trometamol - soluciÓn inyectable - 30 mg inyectable 1 ml - ketorolaco trometamol 30 mg - ketorolaco

KETOROLAC KABI ketorolac trometamol 30 mg/1 mL solution for injection, vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ketorolac kabi ketorolac trometamol 30 mg/1 ml solution for injection, vial

fresenius kabi australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - ketorolac kabi is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dose and method of administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC-BAXTER ketorolac trometamol 30 mg/1 mL solution for injection ampoule Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ketorolac-baxter ketorolac trometamol 30 mg/1 ml solution for injection ampoule

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

TORADOL Ketorolac Trometamol 30mg/1mL injection ampoule Australia - engelsk - Department of Health (Therapeutic Goods Administration)

toradol ketorolac trometamol 30mg/1ml injection ampoule

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory

Ketorolac Baxter 30 mg/ml šķīdums injekcijām Latvia - latvisk - Zāļu valsts aģentūra

ketorolac baxter 30 mg/ml šķīdums injekcijām

baxter holding b.v., netherlands - ketorolacum trometamolum - Šķīdums injekcijām - 30 mg/ml